Entrada Therapeutics, Inc.
TRDA
Rank in Stocks
#17066
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to... Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Share Price
$4.69
Last synced: 2026-11-09
Market Cap
$182.61M
Change (1 day)
-4.09%
Change (1 year)
-39.09%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Entrada Therapeutics, Inc. (TRDA)
Category
Healthcare
EPS for Entrada Therapeutics, Inc. (TRDA)
EPS as of September 2026 TTM: $-3.85
According to Entrada Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-3.85. At the end of 2025 the company had an EPS of $-3.47, a decrease compared to its 2024 EPS of $1.76.
EPS history for Entrada Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.85 | 10.95% |
| 2025 | $-3.47 | -297.16% |
| 2024 | $1.76 | -980.00% |
| 2023 | $-0.20 | -92.83% |
| 2022 | $-2.79 | 74.38% |
| 2021 | $-1.60 | 90.48% |
| 2020 | $-0.84 | -81.08% |
| 2019 | $-4.44 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -506.75% |
US
|
|
| $-7.07 | 83.64% |
US
|
|
| $-5.29 | 37.40% |
AU
|
|
| $12.88 | -434.55% |
BE
|
|
| $21.56 | -660.00% |
NL
|
Questions about Entrada Therapeutics, Inc.'s earnings per share (EPS)
What is Entrada Therapeutics, Inc.'s earnings per share (EPS)?
Entrada Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-3.85, as of Sep 2026.
What was Entrada Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Entrada Therapeutics, Inc.'s earnings per share (EPS) was $-3.47, compared with $1.76 in 2024.
How has Entrada Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Entrada Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($1.76) and lowest in 2025 ($-3.47).
How does Entrada Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Entrada Therapeutics, Inc.'s earnings per share (EPS) ($-3.85) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.